Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b74452a889073845b47a40e23c273814 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-175 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
filingDate |
2019-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d5e1ba9cd30a64b465e9dc6bb7097c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2fdf66f347574e467e65091a071847a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b575a6465cdd3cf7980cb26e205e775a |
publicationDate |
2021-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20210038586-A |
titleOfInvention |
Optimal dosage of diaminophenothiazines in the population |
abstract |
The present invention relates to a leuco-methylthioninium (LMT) compound that maximizes the proportion of subjects whose MT concentration exceeds the concentration at which therapeutic efficacy can be achieved in connection with the treatment of neurodegenerative disorders such as Alzheimer's disease and deep temporal dementia. Provides a novel dosing regimen for. LMT containing dosage units and other compositions are also provided while maintaining the desired clinical profile. |
priorityDate |
2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |